
51 - 200 employees
Founded 2019
🧬 Biotechnology
💊 Pharmaceuticals
🔬 Science
💰 $85M Series B on 2022-01
Biotechnology • Pharmaceuticals • Science
Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. The company is pioneering CAR T-cell therapies, leveraging the transformational power of T cells to potentially provide sustained, treatment-free remission for autoimmune conditions. Kyverna's lead CAR T-cell therapy candidate, KYV-101, is advancing through clinical trials targeting various autoimmune diseases, including multiple sclerosis, myasthenia gravis, systemic sclerosis, and lupus nephritis. Their pipeline features innovative chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats aimed at B cell-driven autoimmune diseases.
Selected: 🆕 Date Added.
🔥 4 hours ago
VP Marketing leading CAR-T commercialization and launch strategy for Kyverna Therapeutics’ autoimmune cell therapies. Building the marketing organization and guiding multi-indication lifecycle expansion.
🇺🇸 United States – Remote
💵 $320k - $350k / year
💰 $85M Series B on 2022-01
⏰ Full Time
🔴 Lead
👔 Vice President
👻 Ghost score 9%
🕒 Yesterday
Director leading Kyverna’s Western US Medical Science Liaison function for cell therapy and autoimmune medicine. Building scientific partnerships, guiding clinical strategy, and mentoring regional MSL teams.
🏄 California, Colorado, +3 more states – Remote
💵 $220k - $250k / year
💰 $85M Series B on 2022-01
⏰ Full Time
🔴 Lead
👨⚕️ Medical Director
👻 Ghost score 9%
🕒 September 23
Senior physician leading CAR T-cell clinical trials for Kyverna Therapeutics, a biopharmaceutical developing autoimmune disease therapies. Overseeing clinical strategy, medical monitoring, data interpretation, and regulatory submissions.
🇺🇸 United States – Remote
💵 $330k - $370k / year
💰 $85M Series B on 2022-01
⏰ Full Time
🟠 Senior
👨⚕️ Medical Director
👻 Ghost score 9%
🕒 September 18
Contract safety writer supporting pharmacovigilance documentation for Kyverna’s autoimmune cell therapies. Drafting FDA responses, safety assessments, advisory committee materials, and regulatory documents.
🇺🇸 United States – Remote
💵 $170 - $190 / hour
💰 $85M Series B on 2022-01
⏳ Contract/Temporary
🟠 Senior
🔴 Lead
✏️ Content Writer
👻 Ghost score 9%
🕒 September 11
Commercial operations leader managing MLR review, Veeva PromoMats assets, conferences and meetings. Supporting Kyverna’s cell-therapy development for autoimmune diseases.
🇺🇸 United States – Remote
💰 $85M Series B on 2022-01
⏰ Full Time
🟠 Senior
⚙️ Operations
👻 Ghost score 19%
🕒 September 10
Cell therapy account specialist driving strategic treatment-center and referral-network adoption for Kyverna Therapeutics’ autoimmune therapies. Supporting patient identification, referrals, readiness, and access across the Pacific territory.
🇺🇸 United States – Remote
💵 $180k - $200k / year
💰 $85M Series B on 2022-01
⏰ Full Time
🟠 Senior
🔴 Lead
💰 Account Manager
👻 Ghost score 9%
🕒 September 10
Cell therapy account specialist leading treatment-center relationships and strategic plans for Kyverna Therapeutics’ autoimmune disease therapies. Driving patient referrals, treatment readiness, and appropriate adoption.
🇺🇸 United States – Remote
💵 $180k - $200k / year
💰 $85M Series B on 2022-01
⏰ Full Time
🟠 Senior
🔴 Lead
💰 Account Manager
👻 Ghost score 9%
🕒 September 10
Cell therapy account specialist driving autoimmune treatment adoption for Kyverna Therapeutics. Managing treatment-center relationships, referral networks, strategic account plans, and launch readiness.
🇺🇸 United States – Remote
💵 $180k - $200k / year
💰 $85M Series B on 2022-01
⏰ Full Time
🟠 Senior
🔴 Lead
💰 Account Manager
👻 Ghost score 9%
🕒 September 10
Cell therapy account specialist supporting Kyverna Therapeutics’ autoimmune disease treatment launch. Managing complex healthcare accounts, referrals, treatment-center readiness, and adoption across the Central/Mountain territory.
🇺🇸 United States – Remote
💵 $180k - $200k / year
💰 $85M Series B on 2022-01
⏰ Full Time
🟠 Senior
🔴 Lead
💰 Account Manager
👻 Ghost score 9%
🕒 August 28
Medical Science Liaison advancing Kyverna Therapeutics’ autoimmune cell-therapy programs. Engaging KOLs, supporting clinical trials, and translating field insights into medical strategy.
🌵 Arizona, Nevada, +1 more states – Remote
💵 $170k - $210k / year
💰 $85M Series B on 2022-01
⏰ Full Time
🟠 Senior
✨ Medical Science Liaison
👻 Ghost score 10%
🕒 August 28
Medical Science Liaison advancing Kyverna’s autoimmune cell therapy programs. Engaging KOLs, supporting clinical trials, and delivering field medical insights.
🌪️ Kansas, New Mexico, +3 more states – Remote
💵 $170k - $210k / year
💰 $85M Series B on 2022-01
⏰ Full Time
🟠 Senior
✨ Medical Science Liaison
👻 Ghost score 10%
🕒 August 28
Medical Science Liaison guiding KOL engagement and clinical-trial support for Kyverna Therapeutics’ autoimmune cell therapies. Communicating CAR-T science and gathering field insights.
🐎 Kentucky, New York, +3 more states – Remote
💵 $170k - $210k / year
💰 $85M Series B on 2022-01
⏰ Full Time
🟠 Senior
✨ Medical Science Liaison
👻 Ghost score 10%
🕒 August 28
Medical Science Liaison advancing Kyverna’s CAR-T therapies for autoimmune diseases. Engaging healthcare professionals, supporting clinical trials, and translating field insights into medical strategy.
🌽 Illinois, Missouri, +1 more states – Remote
💵 $170k - $210k / year
💰 $85M Series B on 2022-01
⏰ Full Time
🟠 Senior
✨ Medical Science Liaison
👻 Ghost score 10%
🕒 August 11
Executive Director leading medical writing for Kyverna Therapeutics, a biopharmaceutical company developing autoimmune disease cell therapies. Overseeing global regulatory documentation, submission strategy, and Medical Writing organization development.
🇺🇸 United States – Remote
💵 $275k - $300k / year
💰 $85M Series B on 2022-01
⏰ Full Time
🔴 Lead
👨⚕️ Medical Director
👻 Ghost score 15%
🕒 August 10
Accounts Payable Specialist managing Coupa vendor onboarding, invoices, payments, and reconciliations. Supporting Kyverna Therapeutics’ autoimmune cell-therapy finance operations through December 2026.
🇺🇸 United States – Remote
💵 $40 - $50 / hour
💰 $85M Series B on 2022-01
⏳ Contract/Temporary
🟡 Mid-level
🟠 Senior
📝 Accounts Payable
👻 Ghost score 15%
🕒 August 9
Director training Medical and Commercial teams for Kyverna Therapeutics, a clinical-stage biopharmaceutical company developing autoimmune cell therapies. Building compliant onboarding, certification, and capability programs for advanced therapy commercialization.
🇺🇸 United States – Remote
💵 $210k - $245k / year
💰 $85M Series B on 2022-01
⏰ Full Time
🔴 Lead
👔 Director
👻 Ghost score 16%
🕒 August 8
Senior medical writer authoring FDA regulatory documents for Kyverna Therapeutics’ autoimmune cell therapy programs. Supporting clinical development, FDA interactions, and regulatory milestones across cross-functional teams.
🇺🇸 United States – Remote
💵 $170k - $190k / year
💰 $85M Series B on 2022-01
⏰ Full Time
🟠 Senior
✏️ Content Writer
👻 Ghost score 16%
🕒 July 8
Executive Director providing regulatory leadership for Kyverna's cell therapy portfolio. Shaping regulatory strategy from development through approval and working with cross-functional teams.
🇺🇸 United States – Remote
💵 $270k - $300k / year
💰 $85M Series B on 2022-01
⏰ Full Time
🔴 Lead
🚔 Compliance
👻 Ghost score 26%
🕒 May 18
Medical Director leading autoimmune CAR T-cell clinical development at Kyverna Therapeutics. Overseeing trials, medical monitoring, regulatory strategy, and clinical data interpretation.
🇺🇸 United States – Remote
💵 $330k - $370k / year
💰 $85M Series B on 2022-01
⏰ Full Time
🟠 Senior
👨⚕️ Medical Director
👻 Ghost score 52%